News
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell ...
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...
ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...
The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer ...
and hold promise to further boost the median survival of patients with EGFR mutated NSCLC. Mutation; Lung cancer; Non-small-cell lung cancer; EGFR; EGFR inhibitor; Precision therapies; Resistance Pie ...
4d
SurvivorNet on MSNNew Drug Combination For Advanced Colon Cancer Highlights The Importance Of Biomarker Testing: What Patients Need To KnowAn ongoing clinical trial called "BREAKWATER" is showing great promise for metastatic colon cancer patients with a particular ...
New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...
AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...
6d
SurvivorNet on MSNTargeted Drug Tagrisso Leads To More Tumor Shrinkage For Lung Cancer Patients With EGFR Mutation: Unpacking The New DataPatients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...
The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...
Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results